Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

Core Insights - Step Pharma has appointed Dr. Karen L. Smith as Chief Medical Officer, effective immediately, to enhance its leadership in targeted cancer treatment through CTPS1 inhibition [1][10] - Dr. Smith brings over 25 years of experience in the healthcare industry, having held senior executive roles in major pharmaceutical companies and successfully overseen over 100 clinical trials and 20 regulatory approvals [2][10] - The appointment follows Step Pharma's recent €38 million Series C financing, positioning the company to advance its clinical development plans for dencatistat across multiple indications [5][10] Company Overview - Step Pharma is a leader in CTPS1 inhibition, focusing on targeted therapies that selectively kill cancer cells while sparing healthy cells [7] - The company was founded in 2014 and is based in Saint-Genis-Pouilly, France, supported by a strong syndicate of investors [8] Leadership and Strategy - Dr. Smith's expertise in clinical development and regulatory affairs is expected to accelerate Step Pharma's 'pipeline in a product' strategy, which aims to provide new treatment options for patients [5][10] - The company aims to transform cancer and blood disorder treatment through innovative approaches, leveraging Dr. Smith's experience to enhance its clinical programs [5][10]